Skip to content

Study · In vitro (cells) · 2006

4 results

Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors.

Tjabringa GS, Ninaber DK, Drijfhout JW, Rabe KF, Hiemstra PS

International archives of allergy and immunology24 Mar 2006Cited by 172 (Europe PMC)

PMID16557028 (opens in a new tab)DOI10.1159/000092305 (opens in a new tab)PepBankPUB-16557028
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In human eosinophils, LL‑37 induced chemotaxis.

    In plain wordsIn lab tests, LL‑37 attracted human eosinophils, a type of white blood cell.

    Peptide
    LL-37
    Outcome
    IncreaseEosinophil chemotaxis
    Study

    humann: not reported in source

    Primary eosinophils and neutrophils from healthy donors
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our results show that LL-37 chemoattracts both eosinophils and neutrophils.
    1 context sentence
    Summary · context
    Neutrophils and eosinophils were obtained from venous blood of healthy donors. Chemotaxis was studied using a modified Boyden chamber technique.
  2. 02LabIn vitro (cells)Activity measurement

    In human neutrophils, LL‑37 induced chemotaxis.

    In plain wordsIn lab tests, LL‑37 attracted human neutrophils, a type of white blood cell.

    Peptide
    LL-37
    Outcome
    IncreaseNeutrophil chemotaxis
    Study

    humann: not reported in source

    Primary eosinophils and neutrophils from healthy donors
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our results show that LL-37 chemoattracts both eosinophils and neutrophils.
    1 context sentence
    Summary · context
    Neutrophils and eosinophils were obtained from venous blood of healthy donors. Chemotaxis was studied using a modified Boyden chamber technique.
  3. 03LabIn vitro (cells)Mechanism

    The formyl-peptide receptor antagonist tBoc-MLP inhibited LL‑37-induced chemotaxis, which indicates that LL‑37 acts through these receptors.

    In plain wordsIn lab tests, blocking formyl-peptide receptors reduced the cell movement caused by LL‑37.

    Peptide
    LL-37
    Outcome
    Not applicableFormyl-peptide receptor involvement in LL-37 chemotaxis
    Study

    humann: not reported in source

    Primary eosinophils and neutrophils from healthy donors
    Comparator
    No antagonist
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The FPR antagonistic peptide tBoc-MLP inhibited LL-37-induced chemotaxis.
    1 context sentence
    Summary · context
    Involvement of formyl-peptide receptors (FPRs) was studied using the antagonistic peptide tBoc-MLP.
  4. 04LabIn vitro (cells)Mechanism

    In human neutrophils, LL‑37 did not activate ERK1/2, whereas the FPR agonist fMLP did.

    In plain wordsIn lab tests, LL‑37 did not switch on ERK1/2 in neutrophils, but fMLP did.

    Peptide
    LL-37
    Outcome
    No significant changeERK1/2 activation in neutrophils
    Study

    humann: not reported in source

    Primary eosinophils and neutrophils from healthy donors
    Comparator
    fMLP (FPR agonist)
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Whereas the FPR agonist fMLP activated ERK1/2 in neutrophils, LL-37 did not, indicating that fMLP and LL-37 deliver different signals through FPRs.
    1 context sentence
    Summary · context
    Activation of the mitogen-activated protein kinase (MAPK) ERK1/2 was studied by Western blotting using antibodies directed against phosphorylated ERK1/2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.